Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Amortization of Deferred Charges (2018 - 2020)

Dna X (SONM) has disclosed Amortization of Deferred Charges for 3 consecutive years, with -$169000.0 as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Amortization of Deferred Charges fell 153.31% year-over-year to -$169000.0, compared with a TTM value of $166000.0 through Dec 2020, down 79.04%, and an annual FY2020 reading of $166000.0, down 54.77% over the prior year.
  • Amortization of Deferred Charges was -$169000.0 for Q4 2020 at Dna X, down from $169000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $386000.0 in Q3 2018 and bottomed at -$169000.0 in Q4 2020.
  • Average Amortization of Deferred Charges over 3 years is $168222.2, with a median of $228000.0 recorded in 2018.
  • The sharpest move saw Amortization of Deferred Charges soared 256.18% in 2019, then plummeted 153.31% in 2020.
  • Year by year, Amortization of Deferred Charges stood at $89000.0 in 2018, then skyrocketed by 256.18% to $317000.0 in 2019, then tumbled by 153.31% to -$169000.0 in 2020.
  • Business Quant data shows Amortization of Deferred Charges for SONM at -$169000.0 in Q4 2020, $169000.0 in Q3 2020, and -$89000.0 in Q2 2020.